Protara Therapeutics, Inc. — Director's Dealing 2015

Jan 8, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2015-01-07

Reporting Person: Gottlieb Daniel Philip (VP Marketing & Business Dev't)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-01-07	Stock Option (Right to Buy)	$10.61	A	26699	Acquired	2025-01-06	Common Stock (26699)	Direct

Footnotes

F1: The shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.